Navigation Links
Starpharma Develops New Gel (Vivagel) To Prevent HIV Transmission

ce as individuals with genital herpes have an increased risk (5 to 7 times greater risk) of contracting the AIDS virus.

A Phase I clinical trial involving the new drug is expected to be launched soon. If the results are satisfactory, the drug would be approved for use in the US, Australia and Europe by the end of 2008.


'"/>




Page: 1 2

Related medicine news :

1. Kirin Develops a Cure for Bird Flu
2. Hungary Develops New Bird Flu Vaccine
3. Dutch chemical group Akzo Nobel Develops A New Bird Flu Vaccine
4. Samsung Develops Device to Measure Body Fat
5. India Develops Test for Diagnosis of Deadly Livestock Disease
6. Mouth Cancer Develops In Two Different Ways
7. John Hopkins Develops An Online Tool To Help In Research Of Certain Rare Diseases
8. Researcher Develops Sensor to Detect E.coli
9. Australian Firm Develops Low Glycaemic Sugar to Prevent Diabetes
10. US Company Develops Better Weight Reduction Pill
11. Rhode Island Biotechnology Company Develops Tularemia Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Starpharma Develops New Gel Vivagel Prevent HIV Transmission

(Date:7/31/2014)... (PRWEB) July 31, 2014 LDM Global ... eDiscovery pricing model that is simplified and predictable with ... size. As a leading international provider of legal ... agencies it has become glaringly apparent that both the ... ballooning eDiscovery budgets and the complex pricing structure that ...
(Date:7/31/2014)... 2014 (HealthDay News) -- With the World Health Organization ... Ebola outbreak has risen to 729, the U.S. ... a travel warning for,the region. The "Level 3 ... affected countries -- Guinea, Liberia and Sierra Leone -- ... is worsening in West Africa," CDC Director Dr. Tom ...
(Date:7/31/2014)... Ontario (PRWEB) July 31, 2014 Setting goals ... seen on blogs on successful tips to weight loss. Fitness ... goals for over 8 years, and has worked with 6000 ... trainers. “We have had the chance to monitor why customers ... stop exercising, how long they stick to their program, whether ...
(Date:7/31/2014)... NY (PRWEB) July 31, 2014 The VitalSleep anti ... lower jaw forward to help open a snorers airway to quiet ... anti-snoring remedy helped her relationship with her husband by allowing ... a 46 years old. My snoring began about 15 years ago ... husband and children could not sleep and had to head downstairs ...
(Date:7/31/2014)... New York (PRWEB) July 31, 2014 ... grow, as Bernstein Liebhard LLP notes that Johnson ... it plans to voluntarily remove its power morcellators ... a report from Bloomberg.com, the company said it ... benefits associated with the devices remain uncertain.* , ...
Breaking Medicine News(10 mins):Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2Health News:CDC Issues Travel Warning as West Africa Ebola Outbreak Worsens 2Health News:Fitness on the Go's Rewards Program Helps Clients Reach Their Goals 2Health News:New Snoring Mouthpiece Reviews from VitalSleep 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 3
... quit, particularly for some teens and African-Americans, who have ... by a team of researchers. , Recent studies have ... have a lower quit rate than comparable smokers of ... suggested in the report is that the menthol effect ...
... ARBOR, Mich. Black people with early stage liver cancer ... disease, according to a new study from the University of ... percent of white liver cancer patients were alive but only ... patients were. Median survival times ranged from 10 months for ...
... surgery for upper airway and digestive track malignant tumors ... based on patient function and survival, according to University ... squamous cell carcinomas account for about 4 percent of ... Currently the standard minimally invasive surgery for these tumors ...
... Reporter , MONDAY, Dec. 20 (HealthDay News) -- Most trauma ... make it to their final destination within the two hours ... patients did make it within the time window, ... study in the December issue of the Archives of ...
... By Steven Reinberg HealthDay Reporter , MONDAY, Dec. ... Americans, a new study shows, despite reported links to an ... "spray-on" tans. In fact, about one in every five ... use indoor tanning, University of Minnesota researchers report. "Tanning ...
... -- Most head and neck cancer patients can speak ... but several factors may be associated with poor outcomes, ... who were assessed nearly three years after they were ... cancer. The U.S. researchers gave a speaking score ...
Cached Medicine News:Health News:Quitting menthol cigarettes may be harder for some smokers 2Health News:Blacks with liver cancer more likely to die, study finds 2Health News:Robotic surgery for head and neck cancer shows promise 2Health News:Most Trauma Patients Not Transferred Within Mandated Time Frame in Illinois 2Health News:Most Trauma Patients Not Transferred Within Mandated Time Frame in Illinois 3Health News: Tanning Beds Still Popular Despite Skin Cancer Risk 2Health News: Tanning Beds Still Popular Despite Skin Cancer Risk 3Health News:Speech, Swallowing Usually OK After Head & Neck Cancer Therapy 2
(Date:7/31/2014)... -- Cryoport, Inc. (OTCBB: CYRX) today announced financial results ... Recent Operating Highlights , Achieved ... month period ended June 30, 2014 compared to the ... further expand Cryoport,s global reach using the ,powered by ... Immudex, an immunotherapy and vaccine development services company, to ...
(Date:7/31/2014)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... 2014, on Thursday, August 7, 2014 before markets open. ... and conference call at 8:00 a.m. Eastern time (5:00 ... the call and webcast to discuss financial results and ... by calling (800) 708-4540 (domestic) or (847) 619-6397 (international), ...
(Date:7/31/2014)...  Celsion Corporation (NASDAQ: CLSN ) announced ... to discuss its second quarter 2014 financial results at ... participate in the call, interested parties may dial 1-800-533-7954 ... and ask for the Celsion Corporation Second Quarter 2014 ... before the call is scheduled to begin. The call ...
Breaking Medicine Technology:Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 2Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 3Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 4Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 5Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 6Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 7Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 8Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2Celsion Corporation to Hold Second Quarter 2014 Financial Results 2
... PARK, N.J., Jan. 25, 2012  Shionogi Inc., the U.S.-based ... results from two studies published online today in the ... first study, a randomized, double-blind, placebo-controlled phase III trial ... with problem drooling due to neurologic conditions demonstrated a ...
...  Amorcyte, LLC, a NeoStem, Inc. company (NYSE Amex: ... of the first patient in the Amorcyte PreSERVE ... study is a multicenter, randomized, double-blind, placebo-controlled clinical ... infarct-related artery infusion of AMR-001, an autologous bone ...
Cached Medicine Technology:Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 2Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 3Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 4Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 5Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 6Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 7Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 8Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 2Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 3Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 4
... with the ultimate space efficient engineering ... new Topcon Express Lane the perfect ... practice environments: Ultimate Space EfficiencyComplete, ergonomically ... an 8' X 9' room without ...
... who need to move their imaging system from ... solution. The IMAGEnet Portable System features a rugged ... monitor. This portable PC solution can be coupled ... be tailored to your multi-site imaging needs. The ...
... combines the best 32-bit software package (IMAGEnet ... offerings to bring you a fast reliable ... efficient "mid-resolution" package takes advantage of the ... the latest graphics capture technology and a ...
Inquire...
Medicine Products: